NervGen Pharma (NGEN) investor relations material

Company overview and business model

• Clinical-stage biopharmaceutical company focused on developing neuroreparative therapeutics for spinal cord injury (SCI) and other neurologic disorders.

• Lead candidate NVG-291 targets CSPGs to enable nervous system repair; currently in Phase 1b/2a clinical trials for SCI.

• No commercial products or revenues; business model centers on drug discovery, development, and eventual commercialization.

• NVG-291 has received Fast Track designation from the FDA and Orphan Drug Designation from the EMA.

• Pipeline includes additional candidates such as NVG-300 for stroke and other neurologic conditions.

Financial performance and metrics

• Net loss of $17.2 million for the nine months ended September 30, 2025; $15.6 million for the same period in 2024.

• Accumulated deficit of $119.9 million as of September 30, 2025.

• Cash and cash equivalents of $11.4 million as of September 30, 2025; $14.5 million raised since then via private placement and warrant/option exercises.

• Pro forma cash position post-placement and exercises: $27.3 million.

• Ongoing negative operating cash flow; future operations dependent on additional financing.

Use of proceeds and capital allocation

• Net proceeds intended for general corporate purposes, including R&D, IP development, preclinical and clinical expenses, and corporate costs.

• May use working capital to fund negative cash flow periods.

• Detailed allocation and milestones to be specified in future prospectus supplements.